Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10278259 | 0.89 | MAPT (0.55) | MAPTALDH1A1TP53HTTCTSB | |
| SCHEMBL3561809 | 0.83 | MAPT (0.58) | MAPTALDH1A1TP53KMT2ARAB9A | |
| SCHEMBL4255322 | 0.82 | CTSB (0.68) | MAPTALDH1A1TP53HTTCTSB | |
| SCHEMBL20522605 | 0.80 | MAPT (0.61) | MAPTALDH1A1TP53HTTCTSB | |
| SCHEMBL3435641 | 0.78 | ALDH1A1 (0.50) | MAPTALDH1A1HTTPOLBMAPK1 | |
| SCHEMBL4706571 | 0.78 | MAPT (0.60) | MAPTALDH1A1TP53HTTCTSB | |
| Benzene SCHEMBL1673960 | 0.77 | CTSB (0.52) | MAPTALDH1A1TP53HTTCTSB | |
| SCHEMBL2491808 | 0.77 | MAPT (0.67) | MAPTALDH1A1TP53HTTCTSB | |
| SCHEMBL2269393 | 0.76 | MAPT (0.55) | MAPTALDH1A1HTTKMT2APOLB | |
| SCHEMBL4104844 | 0.76 | MAPT (0.55) | MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | MAPT 1330/4885ALDH1A1 975/4885TP53 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.